Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15946013 | 0.87 | CA1 (0.40) | CA1CA2KDM4EADRB3ADRA1A | |
| SCHEMBL3130816 | 0.83 | CA1 (0.40) | CA1CA2KDM4EADRB3ADRA1A | |
| SCHEMBL3135807 | 0.81 | AURKA (0.44) | KDM4EADRB3ADRA1AALDH1A1 | |
| SCHEMBL2150463 | 0.77 | HTR6 (0.49) | ADRB3MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2150942 | 0.77 | ADRB2 (0.38) | KDM4EADRB3ADRA1AADRA2BADRA2C | |
| SCHEMBL2150529 | 0.74 | CA1 (0.41) | CA1CA2ADRB3ADRA1AMEN1 | |
| SCHEMBL3137067 | 0.73 | ADRB3 (0.46) | ADRB3ADRA1A | |
| SCHEMBL2151011 | 0.73 | KDM4E (0.40) | KDM4EADRB3KCNH2 | |
| SCHEMBL1710558 | 0.72 | CA1 (0.32) | CA1CA2SMN1; SMN2 | |
| SCHEMBL21239626 | 0.71 | KEAP1 (0.48) | CA1CA2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | CA1 4789/4885CA2 1745/4885KDM4E 4575/4885 |
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | CA1 4789/4885CA2 1745/4885KDM4E 4575/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | CA1 4789/4885CA2 1745/4885KDM4E 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.